StockMarketWire.com - Dual-listed Paris based company Novacyt said it had experienced strong demand for its coronavirus test following the major outbreak of the disease originating in China.
The company launched the test on 31 January, the day after the World Health Organization declared the so-called 2019-nCoV outbreak a global emergency.
To date, company subsidiary Primerdesign had received orders for 33,000 tests and requests for quotations for another 32,000 from over 30 countries, with a high conversion rate from quotations to orders.
Novacyt also announced that it was planning to launch a CE-Mark approved nCoV test in the week commencing 17 February.
At 10:11am: [LON:NCYT] Novacyt S.A share price was +5.5p at 46p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.